Study questions benefit of higher IV phenylbutazone doses
Bottom line
A study in Animals adds to the evidence that more IV phenylbutazone isn’t necessarily better for acute equine foot pain. In a reversible lameness model using eight horses fitted with adjustable heart bar shoes, Jonathan H. Foreman and colleagues compared saline with multiple IV phenylbutazone dose levels and found that a half-dose produced only brief benefit, while full and double doses performed similarly over a 12-hour monitoring period. Earlier reporting of the same work at the 2011 AAEP convention summarized the central takeaway this way: the double dose did not deliver added analgesic benefit in this model, despite the higher exposure. (ivis.org)
Why it matters: For equine veterinarians, the study supports a familiar but important stewardship point: escalating phenylbutazone above standard IV dosing may increase risk without improving pain control. Phenylbutazone remains one of the most commonly prescribed NSAIDs for equine musculoskeletal pain, but adverse effects of NSAIDs in horses, including gastrointestinal injury and renal damage, are tied to dose and duration. Current product labeling also limits IV administration to no more than five successive days. (pmc.ncbi.nlm.nih.gov)
What to watch: Watch for whether this publication changes day-to-day dosing decisions, especially around tapering to lower doses once control is achieved, rather than pushing to higher IV doses. (pmc.ncbi.nlm.nih.gov)
Key facts
- Study type
- Reversible model of equine foot lameness
- Journal
- Animals
- Sample size
- Eight horses
- Intervention
- IV phenylbutazone compared with saline
- Model
- Adjustable heart bar shoes
- Main finding
- Half-dose benefit was brief, and full and double doses were not meaningfully separated over 12 hours
- Earlier presentation
- 2011 AAEP Annual Convention, San Antonio
- Clinical takeaway
- Higher IV phenylbutazone doses did not add analgesic benefit in this model
A newly highlighted Animals paper on IV phenylbutazone dosing in horses reinforces a practical message for equine practice: higher doses may not buy more analgesia. In the study, Jonathan H. Foreman and colleagues tested varying IV phenylbutazone doses against saline in a reversible model of equine foot lameness and found that lower dosing had only short-lived efficacy, while full and double doses were not meaningfully separated over the 12-hour observation window. (ivis.org)
That finding fits with a longer arc of work from the same research group. Foreman’s team previously used the adjustable heart bar shoe model to study single-dose IV phenylbutazone and other NSAIDs in experimentally induced, reversible foot pain, and later presented the phenylbutazone dose-titration data at the 2011 AAEP Annual Convention in San Antonio. The model is designed to create an NSAID-responsive lameness that can be induced and relieved quickly, allowing each horse to serve as its own control and reducing between-horse variation. (onlinelibrary.wiley.com)
The dosing question matters because phenylbutazone is deeply embedded in equine pain management. A recent review describes it as the most prescribed non-selective COX inhibitor for musculoskeletal pain and lameness in horses, with common clinical dosing in the 2.2 to 4.4 mg/kg range every 12 to 24 hours. That same review notes that IV phenylbutazone at 4.4 mg/kg has been shown to improve subjective lameness scores for roughly 2 to 8 hours in mechanically induced lameness, and that PK/PD modeling has helped support a common real-world strategy of starting with a higher short course, then reducing to 2 mg/kg for longer therapy to limit adverse effects. (pmc.ncbi.nlm.nih.gov)
In the AAEP-era summary of the dose-titration study, investigators evaluated saline, a half dose, a single dose, and a double dose, using heart rate elevation and lameness score as outcome measures. The half dose was clinically effective only briefly, while the full and double doses were not separated by added analgesic benefit during the 12-hour monitoring period. Trade coverage at the time noted that the “single IV dose” benchmark in the study was 2 g for a 1,000-pound horse, with the double dose set at 4 g. (ivis.org)
Industry and expert-facing sources have framed the result less as a surprise than as a dose-optimization reminder. An equine pharmacology review published in recent years similarly states that higher doses can prolong effect but do not necessarily improve efficacy, echoing the practical interpretation of Foreman’s work. Regulatory labeling also points in the same direction: FDA-posted DailyMed entries for injectable phenylbutazone specify IV use only and limit IV administration to a maximum of five successive days. (elibrary.mjfveterinarycollege.org)
Why it matters: For veterinarians, this is a clinically useful signal against dose escalation for its own sake. If a standard IV dose is already achieving near-maximal analgesic effect in acute foot pain, moving to a double dose may mainly increase exposure, not benefit. That matters because NSAID toxicity in horses is closely linked to dose and duration, with recognized risks including gastric and colonic injury, right dorsal colitis, and renal damage, especially in compromised patients or when NSAIDs are stacked. In other words, the paper supports pain-management decisions that aim for the lowest effective dose, careful duration limits, and a clear plan for reassessment. (merckvetmanual.com)
There are still caveats. This was an induced, reversible foot pain model in a small number of horses, not a broad field trial across naturally occurring orthopedic disease, laminitis, or post-procedural pain. Even so, the work is useful because it isolates the dosing question cleanly, and it aligns with older chronic-lameness data showing limited separation between standard and higher phenylbutazone dosing in some settings. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next question is whether publication of these data in a journal setting leads to wider uptake in equine protocols, especially around front-loading, tapering, and avoiding reflexive use of double-dose IV phenylbutazone when response at standard dosing is incomplete. (ivis.org)